Portal de investigación
TBI/fludarabine versus busulfan/fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allo-HCT. A study from the ALWP of the EBMT
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Swoboda, R.
- Labopin, M.
- Giebel, S.
- Schroeder, T.
- Kroeger, N.
- Arat, M.
- Savani, B.
- Spyridonidis, A.
- Hamladji, R. M.
- Potter, V.
- Deconinck, E.
- Yakoub-Agha, I.
- Rambaldi, A.
- Ozdogu, H.
- Nagler, A.
- Mohty, M.
Grupos
Abstract
Abstract no disponible
Filiaciones
Filiaciones no disponibles
Cita
Swoboda,R,Labopin,M,Giebel,S,Schroeder,T,Kroeger,N,Arat,M,Savani,B et al. TBI/fludarabine versus busulfan/fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allo-HCT. A study from the ALWP of the EBMT. 48th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT). 2022. CZECH REPUBLIC-MAR 19-23. CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND:SPRINGERNATURE. 2022 p.p. 35-35.